Alto Neuroscience
ANRO
58 hedge funds and large institutions have $199M invested in Alto Neuroscience in 2024 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 13 closing their positions.
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
9.78% more ownership
Funds ownership: 59.42% → 69.2% (+9.8%)
9% more funds holding
Funds holding: 53 → 58 (+5)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
19% less capital invested
Capital invested by funds: $245M → $199M (-$46.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
+$12.2M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$9.11M |
| 3 |
BlackRock
New York
|
+$5.59M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$4.82M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$2.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.67M |
| 2 |
Millennium Management
New York
|
-$1.33M |
| 3 |
ZP
Zimmer Partners
New York
|
-$1.15M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.15M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$976K |
ANRO Hedge Fund Activity: Q2 2024 in Review
58 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Alto Neuroscience (ANRO) for Q2 2024, worth a combined $199M — down 19% from $245M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ANRO positions and 13 closed out — a net gain of 5 holders — while 21 added to existing stakes and 10 trimmed.
The largest buyer was Alkeon Capital Management, opening a new position worth an estimated $12.2M. The largest seller was Citadel Advisors, exiting entirely with an estimated $2.67M sold.
- 58 institutional investors held Alto Neuroscience (ANRO) as of Q2 2024, up from 53 in Q1 2024.
- Funds reported $199M of Alto Neuroscience stock for Q2 2024, down 19% quarter-over-quarter.
- 18 funds opened new Alto Neuroscience positions in Q2 2024 and 13 closed out, a net change of +5 holders.
- The largest Alto Neuroscience buyer in Q2 2024 was Alkeon Capital Management, an estimated $12.2M added.
- The largest Alto Neuroscience seller in Q2 2024 was Citadel Advisors, an estimated $2.67M sold.
Based on aggregated 13F filings for Q2 2024.